Unicycive Therapeutics - צמיחת מכירות משנה לשנה (TTM) UNCY

סמל מסחרי של unicycive.com (UNCY)

Unicycive Therapeutics occupies an untapped niche in nephrology by developing phosphate control agents. GURU.Markets analytics provides this chart of year-over-year sales growth (over 4 quarters), where the 0.00 indicator determines the metric's magnitude. The variety of clinical trial stages minimizes strategic risks, although business development relies exclusively on existing investment capital reserves.

Unicycive (UNCY) - צמיחת מכירות משנה לשנה (TTM) מ-11.02.2024 עד 18.11.2026

Unicycive Therapeutics, Inc - פילוחים אנליטיים ומדדי מפתח (UNCY)

- שווי שוק ותחזית יעד של אנליסטים:
אנליטיקה מסכמת של החברה:UNCY - Unicycive
מוצר סדרתי של Unicycive

The analyst assesses the issuer's credit quality through cash flow dynamics. Responsible bioethics management and ESG standards in Unicycive Therapeutics (UNCY) kidney research create a foundation for long-term sustainability. The current year-over-year (TTM) revenue growth rate measures the percentage change in total sales over a rolling year. This calculation captures the company's ability to scale turnover despite macroeconomic shocks. A positive trend in this indicator confirms market demand and reduces investment risks.